Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 501–600 of 831
Narayan, K. M., Agrawal, N., Du, S. X., Muranaka, J., Bauer, K., Leaman, D. P., Phung, P., Limoli, K. L., Chen, H., Boenig, R. I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052732 · Cited by 17
Mikell, I., & Stamatatos, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049610 · Cited by 17
Drummer, H. E., Hill, M. K., Maerz, A. L., Wood, S., Ramsland, P. A., Mak, J., & Poumbourios, P. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003218 · Cited by 20
Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies
Qi, Y., Jo, S., & Im, W. (2015) · Glycobiology · doi:10.1093/glycob/cwv101 · Cited by 19
Broadly neutralizing antibodies: An approach to control HIV-1 infection
Yaseen, M. M., Yaseen, M. M., & Alqudah, M. A. Y. (2016) · International Reviews of Immunology · doi:10.1080/08830185.2016.1225301 · Cited by 17
Ferreira, R.-C., Grant, O. C., Moyo-Gwete, T., Dorfman, J. R., Woods, R. J., Travers, S. A. A., & Wood, N. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-33390-2 · Cited by 18
Site-Specific Glycosylation of Recombinant Viral Glycoproteins Produced in Nicotiana benthamiana
Margolin, E., Allen, J. D., Verbeek, M., van Diepen, M. T., Ximba, P., Chapman, R. E., Meyers, A. E., Williamson, A., Crispin, M., & Rybicki, E. P. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.709344 · Cited by 19
Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity
Laumaea, A., Marchitto, L., Ding, S., Beaudoin-Bussières, G., Prévost, J., Gasser, R., Chatterjee, D., Gendron‐Lepage, G., Medjahed, H., Chen, H.-C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111983 · Cited by 17
“PG9 recognizes V1V2 epitopes on the trimer apex 40–42 and preferentially interacts with the “closed” Env.”
Endoglycosidases for the Synthesis of Polysaccharides and Glycoconjugates
Li, C., & Wang, L. (2016) · Advances in carbohydrate chemistry and biochemistry · doi:10.1016/bs.accb.2016.07.001 · Cited by 20
Self-citationAhmed, S., Shrivastava, T., Kumar, N., Ozorowski, G., Ward, A. B., & Chakrabarti, B. K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776419 · Cited by 17
“The contact regions primarily include the glycan at Asn-160 and Asn-156 and residue Lys-168 of one protomer and glycans Asn-160 and Asn-197 (V3 loop) of the adjacent protomer (28, 29).”
BackgroundSelf-citationThe Janus Face of Follicular T Helper Cells in Chronic Viral Infections
Greczmiel, U., & Oxenius, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01162 · Cited by 19
Antibodies expose multiple weaknesses in the glycan shield of HIV
Crispin, M., & Bowden, T. A. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2627 · Cited by 16
Wang, W., Zirkle, B., Nie, J., Ma, J., Gao, K., Chen, X. S., Huang, W., Kong, W., & Wang, Y. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000595 · Cited by 16
Nicely, N. I., Wiehe, K. J., Kepler, T. B., Jaeger, F. H., Dennison, S. M., Rerks‐Ngarm, S., Nitayaphan, S., Pitisuttithum, P., Kaewkungwal, J., Robb, M. L., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.016 · Cited by 17
“, 2012), and like PG9 and CH01 (Liao et al., 2013; McLellan et al., 2011) binds the gp120 V2 region involving Lys169.”
BackgroundInfluentialSelf-citationChuang, G., Liou, D., Kwong, P. D., & Georgiev, I. S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku318 · Cited by 20
Self-citationRegistre, L., Moreau, Y., Ataca, S. T., Pulukuri, S. V., Henrich, T. J., Lin, N., & Sagar, M. (2019) · Journal of Virology · doi:10.1128/jvi.01604-19 · Cited by 17
“Passive administration of a V3 loop bnAb (10-1074) decreased plasma viremia and delayed virus reemergence in some, but not all, treated individuals (1–3).”
BackgroundNakamura, K. J., Heath, L., Sobrera, E. R., Wilkinson, T. A., Semrau, K. E. A., Kankasa, C., Tobin, N. H., Webb, N. E., Lee, B., Thea, D. M., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0331-z · Cited by 20
Styles, T. M., Gangadhara, S., Reddy, P. B. J., Hicks, S. L., LaBranche, C. C., Montefiori, D. C., Derdeyn, C. A., Kozlowski, P. A., Velu, V., & Amara, R. R. (2019) · Journal of Virology · doi:10.1128/jvi.00934-19 · Cited by 16
“1) (49) was codon optimized for vaccinia virus expression, synthesized from GeneArt, and cloned into pLW-73 using the XmaI site under the control of an independent mH5 promoter.”
MethodBroadly Neutralizing Bovine Antibodies: Highly Effective New Tools against Evasive Pathogens?
Burke, M. J., Stockley, P. G., & Boyes, J. (2020) · Viruses · doi:10.3390/v12040473 · Cited by 15
“Together, these Abs provide a proof of principle of the mechanisms by which extended CDR H3 structures can nullify evasive viral features by reaching into conformationally restricted regions of the viral glycoprotein [16,29].”
BackgroundInfluentialRange of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies
Kaplan, G., Roitburd‐Berman, A., Lewis, G. K., & Gershoni, J. M. (2016) · Journal of Virology · doi:10.1128/jvi.03206-15 · Cited by 17
Immunogen design to focus the B-cell repertoire
Sattentau, Q. J. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000054 · Cited by 16
“1), is rich in glycans, some of which form elements of these bNAb epitopes [26,28,29], and contains the junction between gp120 protomers [17 && ,18 && ,26].”
BackgroundBos taurus ultralong CDR H3 antibodies
Vadnais, M. L., & Smider, V. V. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.05.004 · Cited by 17
Mabvakure, B. M., Scheepers, C., Garrett, N., Karim, S. S. A., Williamson, C. E., Morris, L., & Moore, P. L. (2018) · Journal of Virology · doi:10.1128/jvi.01685-18 · Cited by 16
Donahue, T. C., Zong, G., O'Brien, N. A., Ou, C., Gildersleeve, J. C., & Wang, L. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00211 · Cited by 16
Self-citationBispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
Zhang, B., Gorman, J., Kwon, Y. D., Pegu, A., Chao, C. W., Liu, T. W. B., Asokan, M., Bender, M. F., Bylund, T., Damron, L. F., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2165390 · Cited by 16
Self-citationNakamura, K. J., Cerini, C., Sobrera, E. R., Heath, L., Sinkala, M., Kankasa, C., Thea, D. M., Mullins, J. I., Kuhn, L., & Aldrovandi, G. M. (2012) · AIDS · doi:10.1097/qad.0b013e32835cadd6 · Cited by 15
“that target distinct but partially overlapping quaternary epitopes on gp120 that include the V1, V2, and V3 loops [30,36,37].”
BackgroundSynergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones
Miglietta, R., Pastori, C., Venuti, A., Ochsenbauer, C., & Lopalco, L. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0346-3 · Cited by 16
“Results In order to assess synergistic enhancement of inhibition by a panel of human neutralizing antibodies with different HIV-1 envelope protein epitope specificity, the study examined six human neutralizing mAbs, recognizing four different env domains; 4E10 and 2 F5 antibodies bind two contiguous epitopes within th…”
BackgroundGorman, J., Mason, R. D., Nettey, L., Cavett, N., Chuang, G., Peng, D., Tsybovsky, Y., Verardi, R., Nguyen, R., Ambrozak, D. R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.007 · Cited by 15
Self-citationManca, F., Fenoglio, D., Valle, M. T., Pira, G. L., Kunkl, A., BALDERAS, R. S., Baccalà, R., Kono, D. H., Ferraris, A. M., Saverino, D., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250513 · Cited by 15
Roark, R. S., Habib, R., Gorman, J., Li, H. J., Connell, A. J., Bonsignori, M., Guo, Y., Hogarty, M. P., Olia, A. S., Sowers, K. J., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250638 · Cited by 23
“However, of the five possible recognition topologies utilizing apex insertion and parallel or antiparallel C-strand hydrogen bonding, alone or in combination, only three topologies have been observed so far: apex insertion alone for PGT145 and PCT64; parallel strand hydrogen bonding for both PG9/16 and CH01 and antipa…”
InfluentialSelf-citationReiss, E. I. M. M., van Haaren, M. M., van Schooten, J., Claireaux, M. A. F., Maisonnasse, P., Antanasijevic, A., Allen, J. D., Bontjer, I., Torres, J. L., Lee, W.-H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00576-9 · Cited by 14
Self-citationImmunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120
Ahmed, M. Z., Rao, T., Mutahir, Z., Ahmed, S., Ullah, N., & Ojha, S. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1480025 · Cited by 21
Nie, J., Wang, W., Wen, Z., Song, A., Hong, K., Lu, S., Zhong, P., Xu, J., Kong, W., Li, J., et al. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.07.011 · Cited by 14
Evans, M. C., Phung, P., Paquet, A. C., Parikh, A., Petropoulos, C. J., Wrin, T., & Haddad, M. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-77 · Cited by 15
“This finding is consistent with previously identified epitopes, in particular for PG-9 and − 16 [4,50,51].”
ResultCandidate Antibody-Based Therapeutics Against HIV-1
Gong, R., Chen, W., & Dimitrov, D. S. (2012) · BioDrugs · doi:10.2165/11631400-000000000-00000 · Cited by 14
“The crystal structure of V1/V2 in complex with PG9 has been solved, which is helpful for identification of conserved features that enable recognition of gp120.([130]) Very recently, plasma bnmAbs specific for epitopes that include carbohydrates and are critically dependent on the glycan at position 332 of Env gp120 we…”
BackgroundLöving, R., Sjöberg, M., Wu, S.-R., Binley, J. Μ., & Garoff, H. (2013) · Journal of Virology · doi:10.1128/jvi.00530-13 · Cited by 14
“these defined much of the epitope (22, 23).”
BackgroundLacerda, M., Moore, P. L., Ngandu, N. K., Seaman, M. S., Gray, E. S., Murrell, B., Krishnamoorthy, M., Nonyane, M., Madiga, M., Wibmer, C. K., et al. (2013) · Virology Journal · doi:10.1186/1743-422x-10-347 · Cited by 15
“Additional structures including the scaffolded V2 structure [44] and particularly future structures of trimeric forms of the envelope would greatly enhance the power of this approach.”
BackgroundSelf-citationYin, Y., Quinlan, B. D., Ou, T., Guo, Y., He, W., & Farzan, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106203118 · Cited by 13
Hoffman, H. K., Aguilar, R. S., Clark, A. R., Groves, N. S., Pezeshkian, N., Bruns, M. M., & van Engelenburg, S. B. (2022) · Journal of Virology · doi:10.1128/jvi.00767-22 · Cited by 16
“For the anti-Env Fabs PGT145 (22, 100), BG18 (56, 57), and PGT151 (46), the coding sequences for the heavy and light chains were synthesized by IDT and cloned into the pCOMB3H-b12 vector in place of the heavy and light chains of b12.”
BackgroundMethodInfluentialHeavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates
He, W., Ou, T., Skamangas, N. K., Bailey, C. C., Bronkema, N., Guo, Y., Yin, Y., Kobzarenko, V., Zhang, X., Pan, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.003 · Cited by 15
Host–pathogen interaction in HIV infection
Chowdhury, A., & Silvestri, G. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.07.003 · Cited by 20
Yen, P.-J., Mefford, M., Hoxie, J. A., Williams, K. C., Desrosiers, R. C., & Gabuzda, D. H. (2014) · Virology · doi:10.1016/j.virol.2014.03.024 · Cited by 14
“Furthermore, N160 is a critical residue in HIV gp120 for recognition and binding of a broadly neutralizing antibody, PG9 (McLellan et al., 2011).”
BackgroundPassive Immunization against HIV/AIDS by Antibody Gene Transfer
Yang, L., & Wang, P. (2014) · Viruses · doi:10.3390/v6020428 · Cited by 16
“Concurrently, Burton and coworkers utilized a clonal B cell culture to screen over 30,000 activated memory B cells from a clade-A-infected African donor and identified two potent bnAbs, PG9 and PG16 [95], that target the V1/V2 loops of the gp120 [96].”
BackgroundO’Rourke, S. M., Sutthent, R., Phung, P., Mesa, K. A., Frigon, N. L., To, B., Horthongkham, N., Limoli, K. L., Wrin, T., & Berman, P. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119608 · Cited by 14
“The locations of glycosylation sites at positions 156 and 160 in the B strand required for the binding of the PG9 MAb [ 20 , 23 ] are indicated .”
BackgroundInfluentialClosing the door to human immunodeficiency virus
Kang, Y., Guo, J., & Chen, Z. (2013) · Protein & Cell · doi:10.1007/s13238-012-2111-9 · Cited by 16
“Both of them contain a long protruding CDR H3 loop penetrating a N-linked glycan shield to variable regions of gp120 (Pancera et al., 2010; McLellan et al., 2011).”
BackgroundTherapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis
Voigt, A., Semenova, T., Yamamoto, J. K., Etienne, V., & Nguyen, C. Q. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0502-3_8 · Cited by 14
Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design
McGuire, A. T. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000548 · Cited by 16
Dotsey, E. Y., Gorlani, A., Ingale, S., Achenbach, C. J., Forthal, D. N., Felgner, P. L., & Gach, J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125581 · Cited by 14
Aiamkitsumrit, B., Sullivan, N. T., Nonnemacher, M. R., Pirrone, V., & Wigdahl, B. L. (2015) · Advances in virus research · doi:10.1016/bs.aivir.2015.04.001 · Cited by 16
Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
Holt, G. T., Gorman, J., Wang, S., Lowegard, A. U., Zhang, B., Liu, T. W. B., Lin, B. C., Louder, M. K., Frenkel, M. S., McKee, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112711 · Cited by 15
Self-citationLiu, L., Wang, W., Yang, L., Ren, H., Kimata, J. T., & Zhou, P. (2012) · Journal of Virology · doi:10.1128/jvi.01038-12 · Cited by 13
“For PG9, the binding affinity with the viral spike is at least 10-fold higher than that with monomeric gp120, whereas for PG16, the difference is at least 100-fold higher (26).”
BackgroundInfluentialTotrov, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094002 · Cited by 13
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs
Bricault, C. A., Kovacs, J. M., Badamchi-Zadeh, A., McKee, K., Shields, J. L., Gunn, B. M., Neubauer, G. H., Ghantous, F., Jennings, J., Gillis, L., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00369-18 · Cited by 14
Self-citationBeretta, M., Moreau, A., Bouvin-Pley, M., Essat, A., Goujard, C., Chaix, M., Hué, S., Meyer, L., Barin, F., & Braibant, M. (2018) · AIDS · doi:10.1097/qad.0000000000001906 · Cited by 16
Han, C., Johnson, J., Dong, R., Kandula, R., Kort, A. J., Wong, M., Yang, T., Breheny, P. J., Brown, G., & Haim, H. (2020) · mBio · doi:10.1128/mbio.00126-20 · Cited by 12
Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines
Wang, Z., Qin, C., Jing Hua, H. U., Guo, X., & Yin, J. (2016) · Virologica Sinica · doi:10.1007/s12250-015-3691-3 · Cited by 13
“VIROLOGICA SINICA 2016, 31 (2): 110–117 DOI: 10.1007/s12250-015-3691-3”
BackgroundInfluentialLuo, K., Liao, H., Zhang, R., Easterhoff, D., Wiehe, K. J., Gurley, T. C., Armand, L. C., Allen, A. A., Holle, T. A. V., Marshall, D. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88522 · Cited by 13
Self-citationAiyegbo, M. S., Shmelkov, E., Dominguez, L., Goger, M. J., Battacharya, S., deCamp, A. C., Gilbert, P. B., Berman, P. W., & Cardozo, T. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170530 · Cited by 14
Sadjadpour, R., Donau, O. K., Shingai, M., Buckler-White, A. J., Kao, S., Strebel, K., Nishimura, Y., & Martin, M. A. (2013) · Journal of Virology · doi:10.1128/jvi.00878-13 · Cited by 13
Singh, A. A., Pillay, P., Naicker, P., Alexandre, K. B., Malatji, K. B., Mach, L., Steinkellner, H., Vorster, J., Chikwamba, R., & Tsekoa, T. L. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.953654 · Cited by 11
“The CAP256-VRC26 bNAbs lineage, like PG9, targets the trimeric variable regions 1 and 2 (V1V2) region of the HIV-1 gp120 envelope glycoprotein (McLellan et al., 2011; Doria-Rose et al., 2014; Bhiman et al., 2015).”
Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies
Pfeifer, N., Walter, H., & Lengauer, T. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000283 · Cited by 12
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence
Wang, Y., Kapoor, P., Parks, R., Silva-Sánchez, A., Alam, S. M., Verkoczy, L. K., Liao, H., Zhuang, Y., Burrows, P. D., Levinson, M. S., et al. (2015) · Immunogenetics · doi:10.1007/s00251-015-0890-x · Cited by 12
“2007), yet in order to penetrate the viral glycan shield (McLellan et al. 2011), some envelope protein-binding bNAbs contain CDR-H3s with lengths of up to 33 amino acids (West et al.”
Self-citationNeutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
Jaworski, J. P., Alejandrina, V., & Chiavenna, S. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00661 · Cited by 13
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Tam, E.-H., Peng, Y., Cheah, M. X. Y., Yan, C., & Xiao, T. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105834 · Cited by 13
Gruell, H., & Klein, F. (2014) · Nature Medicine · doi:10.1038/nm.3567 · Cited by 12
Targeting Glycans on Human Pathogens for Vaccine Design
Krumm, S. A., & Doores, K. J. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_103 · Cited by 15
Liao, H., Li, S., Yu, Y., Yue, Y., Su, K., Zheng, Q., Jiang, N., & Zhang, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03163 · Cited by 12
Glycopeptide Mimetics Recapitulate High‐Mannose‐Type Oligosaccharide Binding and Function
Lusvarghi, S., Ghirlando, R., Wong, C., & Bewley, C. A. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500157 · Cited by 12
Self-citationLiu, C., Zheng, X., & Ye, X. (2016) · ChemMedChem · doi:10.1002/cmdc.201500498 · Cited by 12
Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen
Liu, C., Zhai, C., Zheng, X., & Ye, X. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00224 · Cited by 12
Narasimhulu, V. G. S., Bellamy-McIntyre, A. K., Laumaea, A., Lay, C.-S., Harrison, D. N., King, H. A. D., Drummer, H. E., & Poumbourios, P. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000537 · Cited by 11
“As most of the key PG9 contact residues (Asn156, Asn160, Arg168, and Phe176) (95) are present in both isolates, this suggests that the conformation of this region differs.”
BackgroundHodge, E. A., Chatterjee, A., Chen, C., Naika, G. S., Laohajaratsang, M., Prasad, V. M., & Lee, K. K. (2023) · npj Viruses · doi:10.1038/s44298-023-00002-4 · Cited by 11
“V1/V2 apex-targeting antibodies, exempli fi ed by PGT145, PG9/16, and the CAP256-VRC26 antibodies, are some of the most potent bnAbs against HIV-1 16,17,21,28,29 .”
Bowles, E. J., Schiffner, T., Rosario, M., Needham, G. A., Ramaswamy, M., McGouran, J. F., Kessler, B. M., LaBranche, C. C., McMichael, A. J., Montefiori, D. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114709 · Cited by 13
Nguyen, H. T., Madani, N., Ding, H., Elder, E., Princiotto, A. M., Gu, C., Darby, P., Alin, J., Herschhorn, A., Kappes, J. C., et al. (2017) · Virology Journal · doi:10.1186/s12985-017-0704-x · Cited by 11
Ray, K., Mengistu, M., Orlandi, C., Pazgier, M., Lewis, G. K., & DeVico, A. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01512 · Cited by 11
Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies
Wei, Q., Hargett, A. A., Knoppová, B., Duverger, A. E., Rawi, R., Shen, C., Farney, S. K., Hall, S. D., Brown, R., Keele, B. F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101711 · Cited by 13
“The quantitative ratio of two complex glycans, Hex3HexNAc4Fuc1 and Hex5HexNAc4Fuc1, at NGS with complex glycans (N88, N160; Figure 6D) showed a consistently higher abundance of Hex3HexNAc4Fuc1.”
Self-citationLee, M., Changela, A., Gorman, J., Rawi, R., Bylund, T., Chao, C. W., Lin, B. C., Louder, M. K., Olia, A. S., Zhang, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26579-z · Cited by 11
Self-citationLi, Y., Guo, Y., Cheng, H., Zeng, X., Zhang, X., Sang, P., Chen, B., & Yang, L. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26322 · Cited by 11
“19 The variable loop V1 is located between β A and β B, V2 is located between β C and β D, and the connecting loop L1 is located between β B and β C. Extending from the V1/V2 region and the V3 loop, a four-stranded β -sheet, called the bridging sheet, has been considered as a regulatory switch for…”
BackgroundHumoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
Trinh, H. V., Gohain, N., Pham, P. T., Hamlin, C., Song, H., Sanders‐Buell, E., Bose, M., Eller, L. A., Tovanabutra, S., Michael, N. L., et al. (2019) · Cells · doi:10.3390/cells8040365 · Cited by 10
Hutchinson, J. M., Mesa, K. A., Alexander, D. L., Yu, B., O’Rourke, S. M., Limoli, K. L., Wrin, T., Deeks, S. G., & Berman, P. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01021 · Cited by 11
“They also did not bind to PG16, which was expected because the gp120s were monomeric and lacked the hybrid complex glycans required for PG16 binding (13).”
BackgroundInfluentialImmune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases
Tang, A. F., Enyindah-Asonye, G. M., & Hioe, C. E. (2021) · Vaccines · doi:10.3390/vaccines9020112 · Cited by 10
Vassell, R. A., He, Y., Vennakalanti, P., Dey, A., Zhuang, M., Wang, W., Sun, Y., Biron‐Sorek, Z., Srivastava, I. K., LaBranche, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128562 · Cited by 11
Braibant, M., Gong, E.-Y., Plantier, J., Moreau, T., Alessandri-Gradt, É., Simon, F., & Barin, F. (2013) · AIDS · doi:10.1097/qad.0b013e32835ecb42 · Cited by 11
“We searched for the conservation of residues interacting with PG9 in CAP45 and ZM109 strains, including two glycosylated residues Asn156 or Asn173 (N-Gly156 or N-Gly173) and Asn160 (N-Gly160), and a stretch of cationic residues of strand C making specific electrostatic interactions with negatively charged residues on…”
BackgroundMethodInfluentialEbrahimi, K. H., West, G. M., & Flefil, R. (2014) · Journal of Proteome Research · doi:10.1021/pr500740n · Cited by 12
Morales, J. F., Yu, B., Perez, G., Mesa, K. A., Alexander, D. L., & Berman, P. W. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.003 · Cited by 11
Li, Y., Deng, L., Ai, S.-M., Sang, P., Yang, J. H., Xia, Y.-L., Zhang, Z.-B., Fu, Y., & Liu, S.-Q. (2018) · RSC Advances · doi:10.1039/c8ra00425k · Cited by 11
Antibodies Targeting the Envelope of HIV-1
Mayr, L. M., & Zolla‐Pazner, S. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0025-2014 · Cited by 10
Andrabi, R., Bala, M., Kumar, R., Wig, N., Hazarika, A., & Luthra, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043704 · Cited by 10
Zhang, Y., Yuan, T., Li, J., Zhang, Y., Xu, J., Shao, Y., Chen, Z., & Zhang, M.-Y. (2013) · AIDS · doi:10.1097/qad.0000000000000015 · Cited by 11
“Approximately twelve bnmAbs have been co-crystalized with Env and their neutralizing epitopes determined [18, 20-26].”
BackgroundSattentau, Q. J. (2011) · Nature · doi:10.1038/480324a · Cited by 10
Functional and Protective Role of Neutralizing Antibodies (NAbs) Against Viral Infections
Cheedarla, N., & Hanna, L. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816328-3.00007-6 · Cited by 11
Powell, R. L. R., Weiß, S., Fox, A., Liu, X., Itri, V., Jiang, X., Luo, C. C., Spencer, D. A., Pandey, S., Cheever, T., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01175-20 · Cited by 10
“Details of the design and construction of the immunogens are described separately (34, 52).”
Kumar, R., Deshpande, S., Sewall, L. M., Ozorowski, G., Cottrell, C. A., Lee, W.-H., Holden, L. G., Richey, S. T., Chandrawacar, A. S., Dhiman, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1008977 · Cited by 10
Self-citationWeiß, S., Itri, V., Pan, R., Jiang, X., Luo, C. C., Morris, L., Malherbe, D. C., Barnette, P. T., Alexander, J., Kong, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28450-1 · Cited by 10
Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates
Liu, C., Huo, C., Zhai, C., Zheng, X., Xiong, D., & Ye, X. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00079 · Cited by 10
Zhong, X., & D’Antona, A. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1072702 · Cited by 12
“Regarding the activity, both antibody PG9 and PG16 contained sTyr residue in a unique hammerhead CDRH3 subdomain (Table 1), which showed significantly more potency on neutralization than its unsulfated form (36).”
BackgroundInfluentialWang, D., Tang, J. Y., Tang, J., & Wang, L. (2015) · Molecules · doi:10.3390/molecules20034610 · Cited by 10
“…isolation of a number of glycan-dependent HIV bnAbs from HIV-infected individuals, such as 2G12, PG9/PG16, and other potent bnAbs [1,5,6,10,12,13], strongly suggests that the “glycan shield” of HIV virions may also display important targets for immunological intervention against viral…”
Self-citationChea, L. S., Wyatt, L. S., Gangadhara, S., Moss, B., & Amara, R. R. (2018) · Journal of Virology · doi:10.1128/jvi.01648-18 · Cited by 12
“1) (61) was cloned between two XmaI restriction sites of the plasmid transfer vector pLW-73 and used to recombine into the essential region of the MVA genome (between genes I8R and G1L) under an independent mH5 promoter.”
MethodTarazona, A. A. P., Laurent, E., Taubenschmid, Y., Paireder, M., Acosta, J. A. T., Göritzer, K., Steinkellner, H., & Mach, L. (2019) · Biotechnology Journal · doi:10.1002/biot.201900308 · Cited by 10
Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Gao, N., Gai, Y., Meng, L., Wang, C., Wang, W., Li, X., Gu, T., Louder, M. K., Doria‐Rose, N. A., Wiehe, K. J., et al. (2022) · Advanced Science · doi:10.1002/advs.202200063 · Cited by 8
Self-citation
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.